>
>
Market research for novel oncology drug with NGS vs. IHC diagnostic strategy
Client Problems
-
A mid size biotech company has a drug targeting a rare cancer mutation and wanted to plan an (ideal) CDx test to accompany the drug launch
-
They wanted to determine the current usage and future adoption of different molecular diagnostic platforms (single analyte, NGS and liquid biopsy)
-
Understand the pro’s and con’s of each platform and determine stakeholders (payers and physicians) perceptions
What We Did
-
Determined treatment flow and molecular diagnostics buy-in process
-
Conducted primary market research with stakeholders (oncologists, pathologists, and payers; N=31)
-
Secondary market research to analyze the market and competition
-
Mapped the niche and adoption of diagnostic platforms (single analyte, NGS, liquid biopsy) in academic vs commercial laboratories
Our Results And Insight
-
Patient flow and diagnostic tests buy-in process
-
Determined the drivers and barriers for NGS adoption
-
Current use trends and stakeholder opinions of solid NGS, liquid NGS, and IHC
See other case studies
Commercial Strategy case studies >
Market Research case studies >
Oncology case studies >
Service Areas Details
Market Research (Quantitative and Qualitative Study)
Therapeutic Areas Details
Oncology (diagnostics, NGS, Solid Tumor)
Featured Consultants
